0001209191-21-055745.txt : 20210913 0001209191-21-055745.hdr.sgml : 20210913 20210913190229 ACCESSION NUMBER: 0001209191-21-055745 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210909 FILED AS OF DATE: 20210913 DATE AS OF CHANGE: 20210913 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GADICKE ANSBERT CENTRAL INDEX KEY: 0001134655 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39401 FILM NUMBER: 211250822 MAIL ADDRESS: STREET 1: THE JOHN HANCOCK TOWER STREET 2: 200 CLARENDON STREET, 54TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BioImpact Capital LLC CENTRAL INDEX KEY: 0001687078 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39401 FILM NUMBER: 211250820 BUSINESS ADDRESS: STREET 1: 450 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 6174259200 MAIL ADDRESS: STREET 1: 450 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER NAME: FORMER CONFORMED NAME: MPM Oncology Impact Management LP DATE OF NAME CHANGE: 20161007 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: UBS Oncology Impact Fund L.P. CENTRAL INDEX KEY: 0001691428 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39401 FILM NUMBER: 211250821 BUSINESS ADDRESS: STREET 1: 450 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-425-9200 MAIL ADDRESS: STREET 1: 450 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Oncology Impact Fund (Cayman) Management L.P. CENTRAL INDEX KEY: 0001721036 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39401 FILM NUMBER: 211250819 BUSINESS ADDRESS: STREET 1: 450 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 6174259200 MAIL ADDRESS: STREET 1: 450 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: iTeos Therapeutics, Inc. CENTRAL INDEX KEY: 0001808865 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 139 MAIN STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 857-204-4583 MAIL ADDRESS: STREET 1: 139 MAIN STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-09-09 0 0001808865 iTeos Therapeutics, Inc. ITOS 0001134655 GADICKE ANSBERT C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE MA 02142 0 0 1 0 0001691428 UBS Oncology Impact Fund L.P. C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE MA 02142 0 0 1 0 0001687078 BioImpact Capital LLC C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE MA 02142 0 0 1 0 0001721036 Oncology Impact Fund (Cayman) Management L.P. C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE MA 02142 0 0 1 0 Common Stock 2021-09-09 4 S 0 38028 28.97 D 5863768 I See Footnote Common Stock 2021-09-10 4 S 0 11313 27.86 D 5852455 I See Footnote Common Stock 2021-09-10 4 S 0 11330 28.73 D 5841125 I See Footnote Common Stock 2021-09-13 4 S 0 35785 27.64 D 5805340 I See Footnote Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. The shares were sold as follows: 13,539 by MPM BioVentures 2014, L.P. ("BV 2014"), 466 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 8,551 by MPM BioVentures 2018, L.P. ("BV 2018"), 169 by MPM Asset Management Investors BV2018 LLC ("AM BV2018") and 15,303 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC. BioImpact Capital LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.29 to $29.27 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares are held as follows: 2,029,971 by BV 2014, 107,713 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 69,871 by AM BV2014, 1,282,086 by BV 2018, 54,213 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)"), 25,302 by AM BV2018 and 2,294,612 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. The shares were sold as follows: 4,027 by BV 2014, 139 by AM BV2014, 2,544 by BV 2018, 50 by AM BV2018 and 4,553 by UBS Oncology. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.455 to $28.45 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares are held as follows: 2,025,944 by BV 2014, 107,713 by BV 2014(B), 69,732 by AM BV2014, 1,279,542 by BV 2018, 54,213 by BV 2018(B), 25,252 by AM BV2018 and 2,290,059 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. The shares were sold as follows: 4,034 by BV 2014, 139 by AM BV2014, 2,547 by BV 2018, 51 by AM BV2018 and 4,559 by UBS Oncology. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.46 to $28.91 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares are held as follows: 2,021,910 by BV 2014, 107,713 by BV 2014(B), 69,593 by AM BV2014, 1,276,995 by BV 2018, 54,213 by BV 2018(B), 25,201 by AM BV2018 and 2,285,500 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. The shares were sold as follows: 12,740 by BV 2014, 439 by AM BV2014, 8,046 by BV 2018, 159 by AM BV2018 and 14,401 by UBS Oncology. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.17 to $27.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares are held as follows: 2,009,170 by BV 2014, 107,713 by BV 2014(B), 69,154 by AM BV2014, 1,268,949 by BV 2018, 54,213 by BV 2018(B), 25,042 by AM BV2018 and 2,271,099 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. /s/ Ansbert Gadicke 2021-09-13 /s/ Ansbert Gadicke, managing partner of BioImpact Capital LLC, the general partner of Oncology Impact Fund (Cayman) Management L.P., the general partner of UBS Oncology Impact Fund L.P 2021-09-13 /s/ Ansbert Gadicke, managing partner of BioImpact Capital LLC 2021-09-13 /s/ Ansbert Gadicke, managing partner of BioImpact Capital LLC, the general partner of Oncology Impact Fund (Cayman) Management L.P. 2021-09-13